You are here

Generic Version of Oral Contraceptive Loestrin Available

CORONA, Calif., April 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has launched Microgestin(R) (norethindrone acetate and ethinyl estradiol tablets), a generic version of the oral contraceptive Loestrin(R), marketed by Pfizer. Microgestin(R) is indicated for the prevention of pregnancy and will be launched in 1mg /20mcg and 1.5mg /30mcg strengths. "The launch of Microgestin(R), paired with our previously launched Microgestin(R) FE, completes our full Microgestin(R) line of oral contraceptives," said Joe Papa, President and Chief Operating Officer. "This launch further supplements our extensive oral contraceptive product portfolio consisting of 14 product families and 22 different product strengths."

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs